Lymphopenia
Welcome,         Profile    Billing    Logout  
 18 Companies   15 Products   15 Products   18 Mechanisms of Action   0 Trials   47 News 
  • ||||||||||  Promacta (eltrombopag) / Novartis
    Trial completion date, Trial termination, Trial primary completion date:  Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients (clinicaltrials.gov) -  Mar 18, 2019   
    P2,  N=24, Terminated, 
    Trial completion date: Jun 2020 --> Jun 2017 | Active, not recruiting --> Terminated | Trial primary completion date: May 2019 --> May 2017; retirement of PI
  • ||||||||||  autologous CD34+ cells transduced with WASP lentiviral vector / Genethon, Boston Children's Hospital
    Trial completion, Gene therapy:  Gene Therapy for WAS (clinicaltrials.gov) -  Jun 2, 2018   
    P1/2,  N=5, Completed, 
    Trial completion date: Jun 2020 --> Jun 2017 | Active, not recruiting --> Terminated | Trial primary completion date: May 2019 --> May 2017; retirement of PI Recruiting --> Completed
  • ||||||||||  Trial completion, Trial completion date, Lymphopenia:  Lympho-4: Idiopathic CD4 Lymphocytopenia (clinicaltrials.gov) -  Mar 19, 2018   
    P=N/A,  N=47, Completed, 
    Recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Sep 2017
  • ||||||||||  Enrollment closed, Enrollment change, Trial primary completion date, Lymphopenia:  Lympho-4: Idiopathic CD4 Lymphocytopenia (clinicaltrials.gov) -  Nov 9, 2017   
    P=N/A,  N=47, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Sep 2017 Recruiting --> Active, not recruiting | N=200 --> 47 | Trial primary completion date: Dec 2016 --> Sep 2017
  • ||||||||||  Amevive (alefacept) / Astellas
    Trial termination:  Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) -  Jun 7, 2017   
    P=N/A,  N=3, Terminated, 
    Recruiting --> Active, not recruiting | N=200 --> 47 | Trial primary completion date: Dec 2016 --> Sep 2017 Suspended --> Terminated; drug company is no longer making the drug
  • ||||||||||  Promacta (eltrombopag) / Novartis
    Enrollment closed, Enrollment change, Trial primary completion date:  Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients (clinicaltrials.gov) -  Feb 2, 2017   
    P2,  N=19, Active, not recruiting, 
    N=12 --> 4 Recruiting --> Active, not recruiting | N=50 --> 19 | Trial primary completion date: Jun 2013 --> May 2019
  • ||||||||||  Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
    Trial completion, Enrollment change:  Interleukin-2 Treatment for Wiskott-Aldrich Syndrome (clinicaltrials.gov) -  Sep 6, 2016   
    P1,  N=9, Completed, 
    Recruiting --> Active, not recruiting | N=50 --> 19 | Trial primary completion date: Jun 2013 --> May 2019 Recruiting --> Completed | N=15 --> 9
  • ||||||||||  Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
    Enrollment change:  Interleukin-2 Treatment for Wiskott-Aldrich Syndrome (clinicaltrials.gov) -  Dec 31, 2015   
    P1,  N=15, Recruiting, 
    Active, not recruiting --> Completed | N=12 --> 23 | Trial primary completion date: Jun 2016 --> Dec 2013 N=11 --> 15
  • ||||||||||  Trial primary completion date, Lymphopenia:  Lympho-4: Idiopathic CD4 Lymphocytopenia (clinicaltrials.gov) -  Apr 30, 2015   
    P=N/A,  N=200, Recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Mar 2016 --> Dec 2016
  • ||||||||||  Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
    Trial primary completion date:  Interleukin-2 Treatment for Wiskott-Aldrich Syndrome (clinicaltrials.gov) -  Jan 13, 2015   
    P1,  N=9, Recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Oct 2015 --> Oct 2016
  • ||||||||||  autologous CD34+ cells transduced with WASP lentiviral vector / Genethon, Boston Children's Hospital
    Trial primary completion date, Gene therapy:  Gene Therapy for WAS (clinicaltrials.gov) -  Nov 20, 2014   
    P1/2,  N=5, Recruiting, 
    N=20 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Sep 2017 --> Dec 2014 Trial primary completion date: Dec 2013 --> Dec 2017
  • ||||||||||  temozolomide / Generic mfg.
    Trial completion, Trial primary completion date:  Feasibility of Lymphocyte Reinfusion in Newly Diagnosed High Grade Gliomas (clinicaltrials.gov) -  Aug 12, 2014   
    P=N/A,  N=10, Completed, 
    Completed --> Terminated; Bankruptcy of Drug manufacturer: Drug not available Active, not recruiting --> Completed | Trial primary completion date: Aug 2013 --> Jan 2014
  • ||||||||||  glycosylated recombinant human interleukin-7 (CYT107) / Revimmune
    Trial primary completion date, Lymphopenia:  Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE) (clinicaltrials.gov) -  May 28, 2014   
    P1/2,  N=21, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Aug 2013 --> Jan 2014 Trial primary completion date: Dec 2014 --> May 2014
  • ||||||||||  Gammaplex (intravenous normal human immunoglobulin) / Bio Products Lab
    Trial completion:  A Study to Find Out How Safe and Effective Gammaplex (clinicaltrials.gov) -  May 26, 2014   
    P4,  N=25, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  Gammaplex (intravenous normal human immunoglobulin) / Bio Products Lab
    Enrollment closed:  A Study to Find Out How Safe and Effective Gammaplex (clinicaltrials.gov) -  Mar 21, 2013   
    P4,  N=25, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting